Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$10.68 USD
-0.43 (-3.87%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $10.67 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Sage Therapeutics, Inc. [SAGE]
Reports for Purchase
Showing records 141 - 160 ( 160 total )
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Moving MOUNTAINs - Pivotal Readout Timing Narrowed to 4Q19
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Scaling the Big Mountains in CNS; Initiate at Neutral With $160 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology - Down But Not Out: Looking Ahead to 3Q19 Biotech Reporting
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology - Overcoming Challenges in CNS Drug Development
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
An Uneventful 2Q19 Report Following Pipeline Deep Dive
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
In A FutureCast Age: Thoughts Ahead of SAGE''s R-D Event
Provider: WEDBUSH SECURITIES INC.
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Initiating at OUTPERFORM; CNS Powerhouse Making Its Mark with GABA Modulation
Provider: WEDBUSH SECURITIES INC.
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Fasten Your Seat Belts: Seven Trial Read-outs Before YE17; New PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
SAGE-547 Is Awarded Breakthrough Therapy Designation (BTD) for Postpartum Depression (PPD); Reiterate Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
SAGE-547 STATUS Trial Results Delayed 6-Months, Reiterate Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Initiating Coverage with a Buy and a 12-Month $56 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C